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Mutations in the Ki-ras and TP53 genes are the most frequently observed genetic alterations in col-
orectal cancer (CRC). Ki-ras mutations are mostly found in codons 12 and 13, and less in codon 61.
The majority of the TP53 mutations occur in the core domain which contains the sequence-specific
DNA binding activity of the protein, and they results in loss of DNA binding.
Few centres have sufficient patients to collect detailed information in the large numbers required to
determine the impact of individual ki-ras and TP53 genotypes on outcome. Moreover, it has been
reported that specific genetic alterations, and not any mutation, might play a different biological role
in cancer progression. For these principal reasons, two collaborative studies have been conducted
(the RASCAL and the TP53-CRC Collaborative Studies) with the aim of investigating the prognos-
tic role of any, and specific, Ki-ras and TP53 mutations in CRC progression.
The results obtained from the RASCAL studies suggest that Ki-ras mutations might have an effect
on the survival rate of CRC patients, and that the specific codon 12 glycine/valine mutation might
play a role in the progression of this neoplasia. The results of the TP53-CRC International Colla-
borative Study demonstrate the importance of primary tumor site when analyzing the prognostic
value of TP53 mutations in CRC. In addition, different types of TP53 mutation might play a pivotal
role in determining the biological behavior of CRC from different sites and hence the prognosis of
patients. This meta-analysis produced evidence for interesting tumor site differences in the predictive
value of TP53 mutation for survival benefit from 5FU chemotherapy.
Introduction
The development of colorectal cancer (CRC) is a multi-step
process characterized by the accumulation of genetic altera-
tions [1]. The Fearon and Vogelstein model assumes the invol-
vement of the ki-ras oncogene in the transition from
intermediate adenomas to carcinomas in sporadic CRC and
the TP53 gene in the later events of CRC progression, when
the cancer is more aggressive and is ready to produce metas-
tases [2].
Ras is a proto-oncogene that codifies for a protein of
21 kDa (p21RAS). The Ras protein is activated transiently as
a response to extracellular signals such us growth factors,
cytokines, and hormones which stimulate cell surface recep-
tors [3]. The hallmark of Ras function is a switch between an
inactive state, in which the proteins are bound to guanosine
diphospates (GDP) and an active state in which conversion to
guanosine-triphosphates (GTP) has occurred. Approximately,
90% of the activating mutations were found in codons 12
(wild-type GGT) and 13 (wild-type GGC) of exon 1 identify-
ing these codons as hot spot mutation points. The most
frequently observed types of mutations are G! A transitions
and G! T transversions. The ras gene family is made up of
three different genes, known as Harvey- (H-), Kirsten- (Ki-)
and N-ras. These are located in three different chromosomes
and the expression levels of each one seem to be tissue
specific. In particular, oncogenic mutations of Ki-ras are
involved in 40% (20–50%) of CRC [4–6].
The TP53 gene is a proto-oncogene on chromosome 17.
The normal TP53 protein inhibits the proliferation of cells
with DNA damage. Alterations in both, or sometimes only
one, of its alleles may interfere with this function. P53 point
mutations were found in about 50% of colorectal cancers. The
majority ( 80%) are mis-sense mutations comprising GC to
AT transitions at CpG dinucleotides and occurs principally in
five hotspot codons (175, 245, 248, 273 and 282) [7]. Most of
these TP53 mutations occur in a region of 600 base pairs
including exons 5–8, which contain the nucleotide sequences
preserved during evolution and coding for the amino acids
which are extremely important for the TP53 DNA binding
activity (area II, codons 112–141; area III, 171–181;area IV,
234–258; and area V, 271–286) [8]. Furthermore, several
functional domains, sites of mutations, have been identified
within this region: the L2 loop (codons 163–195), required
for the folding and stabilization of the central part of the pro-
tein; the L3 loop (codons 236–251), and the LSH motif
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(codons 273–286) within which at least two residues (241,
248 and 273, 280, respectively) contact the DNA directly [9]
(Figure 1).
Most studies performed to evaluate the prognostic signifi-
cance of Ki-ras and TP53 mutations in CRCs have taken into
account any mutation of these genes and the results obtained
thus far have proved to be rather discordant [10–16], with
only some of them indicating an influence of these alterations
on DFS and OS rate. Several studies have, in fact, reported a
reduced survival rate in patients with Ki-ras and/or TP53
mutated tumors [10, 11], while others have found no associ-
ation with prognosis [12–16]. One likely explanation of the
difficulty in attributing a prognostic significance to specific
Ki-ras and TP3 mutations is the insufficient statistical power
of the various individual studies. Moreover, over the last few
years it has been reported that specific genetic alterations, and
not any mutation, might play a different biologic role in can-
cer progression. A study which we ourselves published, for
example, reported that codon 12 mutations are associated with
a mucinous phenotype while codon 13 mutations are associ-
ated with a non-mucinous phenotype which is, however, more
aggressive and with greater metastatic potential [17]. With
regard to TP53, several groups have reported that different
types of TP53 mutation are differentially associated with CRC
prognosis. These include mutations in exon 7, codon 245,
conserved areas and the L3 structural domain [17–21].
Furthermore, several important issues should be considered
when evaluating the prognostic significance of TP53
mutations in CRC. First, loss of TP53 function is a late event
in adenoma-carcinoma progression. Second, TP53 mutations
have a different incidence and perhaps also prognostic impact
depending upon the site of origin of the tumor in the large
bowel. The frequency of TP53 mutations is higher in distal
colon and rectal tumors than in proximal colon tumors
[22, 23]. Finally, several clinical studies have reported that
CRC patients with wild-type TP53 derive a survival benefit
from 5-fluorouracil-based chemotherapy but not those with
mutant TP53 [24].
For these reasons, two collaborative studies have been con-
ducted (the RASCAL study and the TP53-CRC Collaborative
Study) with the aim of investigating the prognostic role of
any, and specific, Ki-ras and TP53 mutations in CRC pro-
gression. Both of the studies had considered a large number of
patients from different countries, therefore in view of the mul-
tiple statistical analyses performed, only values where P <0.01
were considered significant.
In particular, the RASCAL study was made up on two prin-
cipal collaborative studies that have been developed in two
different times. The aim of both collaborative studies was to
evaluate the prognostic significance of mutations of exon 1 of
Ki-ras in their entirety; the prognostic significance of specific
mutations in codons 12 and 13 of Ki-ras; the association
between Ki-ras mutations and the traditional clinical
parameters, such as age, sex, tumor site, type of growth,
Dukes’ staging, grading, histological type, vascular invasion
and lymphocyte response.
The aim of the TP53-CRC International Collaborative
Study was, instead, to evaluate the prognostic and predictive
significance of TP53 mutations in CRC according to site of
origin in the large bowel, tumor stage, type of mutation and
use of adjuvant treatment.
The RASCAL study
In the first RASCAL Study [25] the mutational status of
Ki-ras gene was analyzed in 2721 patients collected from
22 centres from 13 different nations. Investigation of the
mutational status of the Ki-ras gene was conducted on DNA
extracted from tumor samples by various methods, for
example, PCR amplification followed by SSCP analyses,
Figure 1. (a) Schematic representation of the TP53 protein structural domains, (b) highly conserved regions of p53 gene and (c) mutation hot spots in
CRC as reported in literature.
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PCR and direct sequencing, PCR with allele-specific primers
and hybridization. In this study, the authors show that
mutations in the Ki-ras gene were important for the pro-
gression and outcome of established colorectal cancer,
although some specific Ki-ras mutations (glycine/valine at
codon 12) seems to have a prognostic role more important
than others.
The RASCAL II study [26] analyzed data regarding 3439
cases of CRC collected from 35 centers from 19 different
nations with a mean follow-up of 55 months. Five hundred
and forty-eight (16%) were at Dukes’ stage A, 1339 (41%) at
stage B, 1056 (31%) at stage C and 436 (12%) at stage D. The
same techniques of the first RASCAL Study were used to
investigate the mutational status of Ki-ras gene. Thirty-five
percent of the cases analyzed showed mutations in the Ki-ras
gene, 26% of which in codon 12 and 9% in codon 13. About
9% of the overall mutations brought about the replacement of
the amino acid glycine with valine in codon 12. The effect of
the mutation was determined by two different methods—first
the specific mutations were compared with other types or with
wild-type, i.e. no mutations, after checking Dukes’ stage, age
and center of origin. Subsequently, the effect of all the
mutations taken in their entirety was compared with that of
the wild-type.
No association was found between Ki-ras mutations and
other clinicopathological variables such as age, sex, tumor
site, type of growth, Dukes’ stage, histological type, vascular
invasion and lymphocyte response. Multivariate analysis
showed that advanced Dukes’ stage, age and the codon 12
glycine/valine mutation were significantly associated with a
poorer prognosis. A separate analysis of the effects of the
codon 12 glycine/valine mutation in patients with stage B or
stage C tumors showed that the mutation brought about a sig-
nificant reduction of the disease-free interval (P = 0.0076,
RR = 1.5) and of survival rate (P= 0.02, RR = 1.45) only in
patients with Dukes’ stage C tumors.
The TP53-CRC collaborative study
In the TP53-CRC Collaborative Study (A. Russo, V. Bazan,
B. Iacopetta, D. Kerr, T. Soussi, N. Gebbia and the ‘TP53-
CRC’ collaborative group#, article in press) data from a total
of 3,583 CRC patients from 17 different countries with infor-
mation on TP53 gene mutation status were collected. Cases
were divided into three groups according to the site of the pri-
mary tumor: 1017 (28%) were proximal colon, 426 (12%)
were distal colon and 2031 (57%) were sigmoid colon and
rectum. Follow-up times (median and range) for patients were
58 months (1–194), 61 months (1–173) and 61 months
(1235) for the proximal colon, distal colon and rectal tumor
groups, respectively. For the mutational analyses a total of
2397 cases were screened by PCR-SSCP followed by sequen-
cing, 158 by PCR-DGGE followed by sequencing, 281
directly by DNA sequencing, 114 by SSCP alone and 454 by
TGGE or DGGE alone. The analyses involved consideration
of any TP53 mutations as well as those specific to exons
4–8 and those in regions coding for the main functional
and structural domains of the protein. Mutations in the hotspot
codons were also examined (codons 175, 196, 213, 245, 248,
249, 273, 282), as well as those in the denaturant codons
known to have a direct effect on TP53 stability (codons 143,
175, 245, 249, 282), those in zinc binding codons (176, 179,
238, 242), those involved with DNA interaction (codons 120,
241, 248, 273, 276, 277, 280, 281, 283) and those involved in
direct DNA contact (codons 248, 282) (). Analysis of point
mutations (missense, nonsense), frameshift mutations (inser-
tions, deletions) and of transitions and transversions was per-
formed. Finally, analysis was performed of mutations that
affect the following classes of amino acids: polar neutral, apo-
lar neutral, basic and acid, together with the type of amino
acid change according to the lateral group. TP53 mutations
were found in 34% of the proximal colon tumors and in 45%
of the distal colon and rectal tumors. TP53 mutations in the
overall CRC cohort or in the three different tumor site groups
did not show significant prognostic value. However the inves-
tigation of different types of TP53 mutation revealed some
interesting associations, particularly for distal colon tumors. In
this group, compared with tumors with wild type TP53 a
poorer outcome was observed for mutations in the LSH
region, denaturing mutations, multiple mutations, or mutations
giving the same amino acid side group or an amino acid loss.
For proximal colon tumors, only TP53 mutations in exon 5
were significantly associated with worse survival and for rec-
tal tumors only those giving rise to an amino acid loss. In
multivariate analysis adjusted for Dukes’ stage, nodal status,
histological grade and lymphatic invasion, only TP53 mutation
associated with an amino acid loss in distal colon tumors was
an independent factor for worse survival (RR = 2.52, 95% CI
[1.28–4.93], P = 0.007). A trend toward statistical significance
for poorer outcome was also observed for exon 5 mutations in
proximal colon tumors (RR = 1.36, 95% CI [1.03–1.79],
P= 0.03).
Finally, for Dukes’ C patients with wild-type TP53,
those treated with chemotherapy showed a significantly bet-
ter survival rate in proximal colon and rectal tumor groups
(Figures 2 & 3), whereas only a trend toward statistical sig-
nificance (P= 0.022) was observed for the distal colon
tumors (Figure 4). For patients with mutated TP53, a better
survival rate with chemotherapy was only observed for the
proximal colon tumor group. TP53 mutation had no prog-
nostic value within patient groups treated by surgery alone
or in those treated with surgery and chemotherapy.
Conclusions
The results obtained from the RASCAL studies suggest that
Ki-ras mutations might have an effect on the survival rate of
CRC patients, and that the specific codon 12 glycine/valine
mutation might play a role in the progression of this neoplasia,
thus leading to a higher risk of disease relapse or death in
30%. Furthermore, when this mutation is present in Dukes’
stage C tumors, this risk goes up as far as 50%.
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The results of the TP53-CRC International Collaborative
Study demonstrate the importance of primary tumor site when
analyzing the prognostic value of TP53 mutations in CRC. In
addition, different types of TP53 mutation might play a pivo-
tal role in determining the biological behavior of CRC from
different sites and hence the prognosis of patients. This meta-
analysis produced evidence for interesting tumor site
differences in the predictive value of TP53 mutation for survi-
val benefit in Dukes’ C patients from 5FU chemotherapy.
In the light of these findings, further trials are therefore
justified to evaluate the predictive significance of Ki-ras and
TP53 mutations. These would require sufficient patient num-
bers to allow multivariate analysis and would preferably
involve homogenous treatment regimens and standardized
mutation screening techniques.
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Figure 3. Only Dukes’ C patients (N = 468) with wt TP53 rectal cancer
showed significantly improved overall survival (P<0.001) if treated with
chemotherapy 7 radiotherapy.
Figure 4. Only Dukes’ C patients (N = 62) with wt TP53 distal colon
cancer showed significantly improved overall survival (P<0.022) if treated
with chemotherapy.
Figure 2. Dukes’ C patients with both wt (A, N = 161) and mutated
(B, N = 138) TP53 proximal colon cancer showed significantly improved
overall survival (P= 0.006 and P<0.001respectively) if treated with
chemotherapy.
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